![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DL Gustafson, HD Beall, EM Bolton, D Ross and CA Waldren
Department of Radiological Health Sciences, Colorado State University, Fort Collins 80523. dgustafson@vines.colostate.edu
Previous studies have indicated that NAD(P)H: quinone oxidoreductase [DT-diaphorase (NQO1)] plays an important role in the bioreductive activation of quinone-containing antitumor agents. Although these studies demonstrated that purified NQO1 can reduce these compounds in vitro, the importance of NQO1 in the intracellular activation of quinone-containing antitumor agents remains controversial. In our study, we transfected human NQO1 into Chinese hamster ovary cells that do not normally express NQO1 activity and obtained stable clones that expressed NQO1 activity of 19-3527 nmol of 2,6-dichlorophenolindophenol reduced/min/mg of protein. The level of NQO1 expression correlated with an increased killing by streptonigrin, EO9 (3-hydroxymethyl-5- aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propen ol), and 2,5- diaziridinyl-3,6-dimethyl-1,4-benzoquinone, but mitomycin C sensitivity was independent of this activity. NQO1 expression also led to a slight decrease in the sensitivity of cells to menadione. Our data demonstrate that compounds that are efficient substrates for NQO1 in vitro are also bioactivated in cultured mammalian cells when they are transfected with human NQO1. These results are consistent with the relative abilities of mitomycin C, streptonigrin, EO9, and 2,5-diaziridinyl-3,6-dimethyl-1,4- benzoquinone to serve as substrates for bioreduction by human NQO1, and show that NQO1 levels are not necessarily predictive in terms of sensitivity to mitomycin C.
This article has been cited by other articles:
|
|
 |
|
  D. Siegel, D. L. Gustafson, D. L. Dehn, J. Y. Han, P. Boonchoong, L. J. Berliner, and D. Ross NAD(P)H:Quinone Oxidoreductase 1: Role as a Superoxide Scavenger Mol. Pharmacol., May 1, 2004; 65(5): 1238 - 1247. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. L. Dehn, S. L. Winski, and D. Ross Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones: Evaluation of the Activity of RH1 Clin. Cancer Res., May 1, 2004; 10(9): 3147 - 3155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Dehn, D. Siegel, E. Swann, C. J. Moody, and D. Ross Biochemical, Cytotoxic, and Genotoxic Effects of ES936, a Mechanism-Based Inhibitor of NAD(P)H:quinone Oxidoreductase 1, in Cellular Systems Mol. Pharmacol., September 1, 2003; 64(3): 714 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Gustafson, D. Siegel, J. C. Rastatter, A. L. Merz, J. C. Parpal, J. K. Kepa, D. Ross, and M. E. Long Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1079 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Baumann, W. F. Hodnick, H. A. Seow, M. F. Belcourt, S. Rockwell, D. H. Sherman, and A. C. Sartorelli Reversal of Mitomycin C Resistance by Overexpression of Bioreductive Enzymes in Chinese Hamster Ovary Cells Cancer Res., November 1, 2001; 61(21): 7770 - 7776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Sharp, L. R. Kelland, M. R. Valenti, L. A. Brunton, S. Hobbs, and P. Workman Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo Mol. Pharmacol., November 1, 2000; 58(5): 1146 - 1155. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Siemankowski, J. Morreale, B. D. Butts, and M. M. Briehl Increased Tumor Necrosis Factor-{{alpha}} Sensitivity of MCF-7 Cells Transfected with NAD(P)H:Quinone Reductase Cancer Res., July 1, 2000; 60(13): 3638 - 3644. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. P. Schelonka, D. Siegel, M. W. Wilson, A. Meininger, and D. Ross Immunohistochemical Localization of NQO1 in Epithelial Dysplasia and Neoplasia and in Donor Eyes Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1617 - 1622. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. J. Pink, S. M. Planchon, C. Tagliarino, M. E. Varnes, D. Siegel, and D. A. Boothman NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of beta -Lapachone Cytotoxicity J. Biol. Chem., February 25, 2000; 275(8): 5416 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Cross, J. C. Deak, E. A. Rich, Y. Qian, M. Lewis, L. A. Parrott, K. Mochida, D. Gustafson, S. Vande Pol, and D. J. Templeton Quinone Reductase Inhibitors Block SAPK/JNK and NFkappa B Pathways and Potentiate Apoptosis J. Biol. Chem., October 29, 1999; 274(44): 31150 - 31154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Belcourt, W. F. Hodnick, S. Rockwell, and A. C. Sartorelli The Intracellular Location of NADH:Cytochrome b5 Reductase Modulates the Cytotoxicity of the Mitomycins to Chinese Hamster Ovary Cells J. Biol. Chem., April 10, 1998; 273(15): 8875 - 8881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Siegel, E. M. Bolton, J. A. Burr, D. C. Liebler, and D. Ross The Reduction of alpha -Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of alpha -Tocopherolhydroquinone as a Cellular Antioxidant Mol. Pharmacol., August 1, 1997; 52(2): 300 - 305. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. T. Puck, R. Johnson, and S. Rasumussen A system for mutation measurement in mammalian cells: Application to gamma -irradiation PNAS, February 18, 1997; 94(4): 1218 - 1223. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
